Silk Road Medical (NSDQ:SILK) this week posted third-quarter results that beat the overall consensus on Wall Street.
The Sunnyvale, California-based stroke treatment tech company reported net losses of $10.3 million, or -29¢ per share, on sales of $37.4 million for the three months ended Sept. 30, on sales growth of 51.31% and profit gain from net losses of $13.9 million in Q3 2021.
Earnings per share were 14¢ ahead of The Street, where analysts were looking for sales of $33.64 million.
“Our performance in the third quarter reflects broad-based U.S. TCAR strength as we capitalize on the operational infrastructure our team has worked so hard to establish,” CEO Erica Rogers said in a news release. “This is the first time in over seven decades that the carotid artery disease market has experienced a level playing field for a minimally invasive approach with open surgery. With TCAR now available to all eligible patients, we have cemented the foundation to es…